AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 15124669
Drug: Standard-dose AraC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose AraC during induction therapy
Trial: 15124669
Drug: No G-CSF
RxNorm normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No G-CSF priming
Trial: 7913644
Drug: Metipranolol (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metipranolol (3 mg/ml)
Trial: 7913644
Drug: Clonidine (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine (2.5 mg/ml)
Trial: 7913644
Drug: Clonidine (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine (2.5 mg/ml) and Metipranolol (3 mg/ml)
Trial: 23200592
Drug: Lung volume
RxNorm normalized name: beef lung preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lung volume reduction coil treatment (LVRC)
Trial: 17425783
Drug: Abatacept (750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abatacept (750 mg infusion)
Trial: 17425783
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (vaccines on day 1 only)
Trial: 9500570
Drug: acute hyperglycemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: acute hyperglycemic hyperinsulinemia (HG) with plasma glucose at 15 mmol/L
Trial: 9500570
Drug: euglycemic hyperinsulinemia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: euglycemic hyperinsulinemia (HI) with plasma insulin at 80 mU/L and glucose at 4 to 5 mmol/L
Trial: 9500570
Drug: intravenous (i.v.)
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous (i.v.) saline (control)
Trial: 343509
Drug: Theophylline ethylenediamine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline ethylenediamine, 400 mg orally
Trial: 343509
Drug: Bendroflumethiazide, 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bendroflumethiazide, 5 mg orally
Trial: 24582466
Drug: Other treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other treatment groups
Trial: 22430457
Drug: Shifts in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shifts in BMI category (e.g., overweight to healthy weight)
Trial: 22430457
Drug: Shifts in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shifts in BMI category (e.g., healthy weight to overweight)
Trial: 11712773
Drug: INVEST (treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INVEST (treatment for 12 months)
Trial: 9613267
Drug: Intrathecal diamorphine
RxNorm normalized name: Diamorphine
DrugBank: Diamorphine (DB01452)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal diamorphine 0.125 mg
Trial: 9613267
Drug: Intrathecal diamorphine
RxNorm normalized name: Diamorphine
DrugBank: Diamorphine (DB01452)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal diamorphine 0.375 mg
Trial: 7815243
Drug: Ursodeoxycholic acid
RxNorm normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodeoxycholic acid (10-12 mg/kg/day)
Trial: 7815243
Drug: Ursodeoxycholic acid
RxNorm normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodeoxycholic acid with taurine (18-22 mg/kg/day)
Trial: 1662233
Drug: 250 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg/kg IVIG (Gammagard)
Trial: 1662233
Drug: 500 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg/kg IVIG (Gammagard)
Trial: 373921
Drug: Domperidone 2
RxNorm normalized name: Domperidone
DrugBank: Domperidone (DB01184)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Domperidone 2 mg/ml injected IV 1 hour before cytostatic treatment and again 4 hours later
Trial: 373921
Drug: Placebo injected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo injected IV 1 hour before cytostatic treatment and again 4 hours later
Trial: 373921
Drug: Domperidone 2
RxNorm normalized name: Domperidone
DrugBank: Domperidone (DB01184)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Domperidone 2 mg/ml
Trial: 26032934
Drug: Chemical peeling
RxNorm normalized name: orange peel extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemical peeling combined with physical effect (4% AHA solution)
Trial: 22277458
Drug: High-dose dabigatran
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose dabigatran
Trial: 22277458
Drug: Low-dose dabigatran
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose dabigatran
Trial: 25739533
Drug: Dabigatran (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dabigatran (both doses)
Trial: 10569322
Drug: treatment effects
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: treatment effects on ambulatory ischemia
Trial: 6349651
Drug: Meclofenamate sodium
RxNorm normalized name: Meclofenamate Sodium
DrugBank: Meclofenamic acid (DB00939)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Meclofenamate sodium (300 mg per day for 6 weeks)
Trial: 6349651
Drug: Phenylbutazone (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenylbutazone (500 mg per day for 1 week and 300 mg per day for 5 weeks)
Trial: 6349651
Drug: Naproxen (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen (500 mg per day for 6 weeks)
Trial: 28602417
Drug: Short-course radiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short-course radiation therapy (25 Gy in 5 fractions, arm 1)
Trial: 28602417
Drug: Commonly used
RxNorm normalized name: Common carp
DrugBank: Common carp (DB10614)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Commonly used radiation therapy (40 Gy in 15 fractions, arm 2)
Trial: 26261149
Drug: Removal of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Removal of dental materials in patients with oral lichenoid lesions (13 patients consented to removal)
Trial: 26261149
Drug: Patch tests
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patch tests for dental restoration materials
Trial: 11054013
Drug: Topical furosemide
RxNorm normalized name: Furosemide
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical furosemide after surgical treatment
Trial: 11054013
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment after surgical treatment (Control)
Trial: 9296823
Drug: Electrocauthery plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electrocauthery plus immunotherapy
Trial: 26703894
Drug: Hyperbaric oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric oxygen therapy (100% oxygen at 2.4 ATA)
Trial: 8878069
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human growth hormone (0.25‐0.5 U/kg/week)
Trial: 1959783
Drug: Weekly cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly cisplatin in combination with epirubicin
Trial: 1959783
Drug: Weekly cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly cisplatin in combination with etoposide
Trial: 6318351
Drug: Bi‐Profenid 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bi‐Profenid 150 mg (two daily doses of 150 mg)
Trial: 6318351
Drug: Indomethacin (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (two daily doses of 50 mg)
Trial: 29429593
Drug: BDP/FF/G (beclometasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BDP/FF/G (beclometasone dipropionate, formoterol fumarate, and glycopyrronium) 87 μg/5 μg/9 μg, two inhalations per day
Trial: 29429593
Drug: IND/GLY (indacaterol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IND/GLY (indacaterol plus glycopyrronium) 85 μg/43 μg, one inhalation per day
Trial: 27614902
Drug: State EITC
RxNorm normalized name: CLOZAPINE (GOLDEN STATE)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: State EITC supplements
Trial: 27614902
Drug: State EITC
RxNorm normalized name: CLOZAPINE (GOLDEN STATE)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: State EITC supplements for a family of three
Trial: 18602526
Drug: Fosinopril treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fosinopril treatment for 3 months
Trial: 15809548
Drug: Inhaled bronchodilator
RxNorm normalized name: Bronchodil
DrugBank: Reproterol (DB12846)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled bronchodilator (albuterol/ipratropium bromide solution)
Trial: 10965009
Drug: Bolus intrathecal
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus intrathecal injections of 50 microg of baclofen
Trial: 10965009
Drug: Bolus intrathecal
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus intrathecal injections of 75 microg of baclofen
Trial: 10965009
Drug: Continuous intrathecal
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intrathecal administration of baclofen via subcutaneous pump
Trial: 8791041
Drug: Flunitrazepam (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flunitrazepam (1 mg intravenous)
Trial: 1611810
Drug: 0.1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg/kg midazolam intravenously in 15 minutes
Trial: 1611810
Drug: 0.15 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.15 mg/kg alpha-hydroxymidazolam intravenously in 15 minutes
Trial: 1611810
Drug: 7.5 mg
RxNorm normalized name: biotin 7.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 mg midazolam orally
Trial: 6231156
Drug: Intravenous saralasin
RxNorm normalized name: saralasin
DrugBank: Saralasin (DB06763)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous saralasin (0.5, 1 and 5 micrograms min‐1 kg‐1) in tetraplegic patients
Trial: 6231156
Drug: Intravenous saralasin
RxNorm normalized name: saralasin
DrugBank: Saralasin (DB06763)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous saralasin (5 micrograms kg‐1 min‐1) in tetraplegic patients after alpha‐adrenoceptor blockade with thymoxamine (1 mg kg‐1 h‐1)
Trial: 6231156
Drug: Intravenous saralasin
RxNorm normalized name: saralasin
DrugBank: Saralasin (DB06763)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous saralasin in both groups (tetraplegic patients and normal subjects)
Trial: 29623135
Drug: High-Flow Oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-Flow Oxygen Therapy (HFO)
Trial: 29623135
Drug: Mask Oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mask Oxygen Therapy
Trial: 27015606
Drug: Immediate triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate triple therapy (IT)
Trial: 27015606
Drug: Step-up triple
RxNorm normalized name: STEP 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Step-up triple therapy (ST)
Trial: 18586124
Drug: Progressive resistance
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Progressive resistance training (supervised, group program, 6 exercises using weight machines, performed twice a week for 10 weeks, 2-3 sets of 10-12 repetitions until fatigue)
Trial: 9661603
Drug: pamidronate (APD)
DrugBank: Pamidronic acid (DB00282)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: pamidronate (APD) 30 mg i.v. every 3 months for 2 yr
Trial: 2699997
Drug: L-carnitine supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-carnitine supplementation (2 grams added to dialysis bath for three months) during acetate hemodialysis
Trial: 2699997
Drug: L-carnitine supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-carnitine supplementation (2 grams added to dialysis bath for three months) during bicarbonate hemodialysis
Trial: 832179
Drug: Intramuscular atropine
RxNorm normalized name: Atropine
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular atropine as the only premedication
Trial: 832179
Drug: Intravenous atropine
RxNorm normalized name: Atropine
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous atropine at the time of induction of anaesthesia
Trial: 29534997
Drug: 4 months
RxNorm normalized name: leuprolide 30 mg/4 months intramuscular kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 months of monthly degarelix (first dose 240 mg, subsequent doses 80 mg per month)
Trial: 29534997
Drug: 10 months
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 months of monthly degarelix (first dose 240 mg, subsequent doses 80 mg per month)
Trial: 29534997
Drug: 4 months
RxNorm normalized name: leuprolide 30 mg/4 months intramuscular kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 months of monthly degarelix
Trial: 29534997
Drug: 10 months
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 months of monthly degarelix
Trial: 26728893
Drug: AZD2327 (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD2327 (3 mg BID)
Trial: 25109239
Drug: Zonisamide (200-500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zonisamide (200-500 mg/day)
Trial: 25109239
Drug: Carbamazepine (400-1,200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbamazepine (400-1,200 mg/day)
Trial: 29705869
Drug: Suvorexant 10
RxNorm normalized name: suvorexant 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suvorexant 10 mg
Trial: 31992394
Drug: Suvorexant 20
RxNorm normalized name: suvorexant 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suvorexant 20 mg
Trial: 26039969
Drug: Suvorexant 40
RxNorm normalized name: Suvorexant
DrugBank: Suvorexant (DB09034)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Suvorexant 40 mg
Trial: 29705869
Drug: Suvorexant 80
RxNorm normalized name: Suvorexant
DrugBank: Suvorexant (DB09034)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Suvorexant 80 mg
Trial: 23197752
Drug: Suvorexant (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suvorexant (all doses combined)
Trial: 18557167
Drug: Magnesium sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Magnesium sulfate infusion (30 mg/kg over 10 minutes, then 10 mg/kg/hr throughout surgery)
Trial: 15784063
Drug: Nefazodone (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nefazodone (300 mg/day)
Trial: 20186295
Drug: Ketamine 2
RxNorm normalized name: esketamine 28 mg nasal spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine 2 mg.kg(‐1)
Trial: 12641685
Drug: Ketamine 2
RxNorm normalized name: esketamine 28 mg nasal spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine 2 mg.kg(‐1) + Midazolam 0.1 mg.kg(‐1)
Trial: 12641685
Drug: Ketamine 2
RxNorm normalized name: esketamine 28 mg nasal spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine 2 mg.kg(‐1) + Midazolam 0.2 mg.kg(‐1)
Trial: 12641685
Drug: Ketamine 1
RxNorm normalized name: ketamine 10 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine 1 mg.kg(‐1) + Midazolam 0.2 mg.kg(‐1)
Trial: 10594542
Drug: Intravenous prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous prednisolone 80 mg
Trial: 2072220
Drug: Penicillin therapy
RxNorm normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Penicillin therapy only
Trial: 6134298
Drug: Oral temazepam
RxNorm normalized name: Temazepam
DrugBank: Temazepam acetate (DB14671)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral temazepam (20 mg)
Trial: 30447052
Drug: Resistin concentration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resistin concentration ≥ 11.4 ng/mL
Trial: 30447052
Drug: Resistin concentration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resistin concentration above 11 ng/mL
Trial: 30308428
Drug: LEV-ER (extended-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LEV-ER (extended-release levetiracetam)
Trial: 30308428
Drug: LEV-IR (immediate-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LEV-IR (immediate-release levetiracetam)
Trial: 27468543
Drug: A &
RxNorm normalized name: A & D OINT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A & As particle 15.2 g/day
Trial: 16534240
Drug: 100 microg
RxNorm normalized name: Digoxin 100 microgram oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 microg intravenously administered CRH
Trial: 16534240
Drug: 12 mg
RxNorm normalized name: pectin 12 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 mg naloxone
Trial: 9635603
Drug: Indomethacin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (50 mg three times a day)
Trial: 1656040
Drug: Lisinopril (10-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril (10-20 mg once daily)
Trial: 12011663
Drug: Valsartan (80-160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan (80-160 mg once daily)
Trial: 10850318
Drug: 500 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg/m2 amifostine intravenously prior to HD-RIT
Trial: 10850318
Drug: 200 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg/kg amifostine prior to HD-RIT in rabbits
Trial: 1936073
Drug: Rokitamycin 200
RxNorm normalized name: rokitamycin
DrugBank: Rokitamycin (DB13409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rokitamycin 200 mg
Trial: 1936073
Drug: Rokitamycin 300
RxNorm normalized name: rokitamycin
DrugBank: Rokitamycin (DB13409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rokitamycin 300 mg
Trial: 1936073
Drug: Rokitamycin 400
RxNorm normalized name: rokitamycin
DrugBank: Rokitamycin (DB13409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rokitamycin 400 mg
Trial: 1936073
Drug: Rokitamycin 600
RxNorm normalized name: rokitamycin
DrugBank: Rokitamycin (DB13409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rokitamycin 600 mg
Trial: 29525393
Drug: Intervention (active
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention (active vitamin D sterol dose increase)
Trial: 27508314
Drug: Comprehensive Reminder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comprehensive Reminder System (health belief education, calendar handbook, weekly automated SMS, four telephone follow-ups)
Trial: 24886036
Drug: Lecithinized superoxide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lecithinized superoxide dismutase (40 or 80 mg)
Trial: 24886036
Drug: Lecithinized superoxide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lecithinized superoxide dismutase (80 mg)
Trial: 20563466
Drug: Morphine PCA
RxNorm normalized name: lauryl PCA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine PCA alone (Group A)
Trial: 20563466
Drug: Morphine PCA
RxNorm normalized name: lauryl PCA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine PCA plus continuous infusion (Group B)
Trial: 18520951
Drug: Fosinopril/hydrochlorothiazide combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fosinopril/hydrochlorothiazide combination (10/12.5 mg titrated up to 20/12.5 mg)
Trial: 18520951
Drug: Amlodipine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine (5 mg titrated up to 10 mg)
Trial: 6373155
Drug: Indapamide (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indapamide (2.5 mg)
Trial: 15939732
Drug: Intravenous aminophylline
RxNorm normalized name: Aminophylline
DrugBank: Aminophylline (DB01223)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous aminophylline 0.5 mg/kg/hour after an appropriate loading dose
Trial: 12463729
Drug: Galantamine and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Galantamine and risperidone administered together
Trial: 12463729
Drug: Galantamine and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Galantamine and risperidone administered alone
Trial: 7851589
Drug: 16 mg
RxNorm normalized name: escin 16 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16 mg oral 6-alpha-methylprednisolone for four evenings starting the evening of retrieval or the evening before thawing cryopreserved embryos, plus 250 mg oral tetracycline four times per day for 4 days.
Trial: 7851589
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered in an identical fashion, plus 250 mg oral tetracycline four times per day for 4 days.
Trial: 6127319
Drug: Tobramycin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tobramycin (1 mg/kg body weight)
Trial: 6127319
Drug: Tobramycin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tobramycin (1 mg/kg body weight) + Cefotaxime (2 g)
Trial: 10150322
Drug: Cefotaxime (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefotaxime (2 g)
Trial: 23351827
Drug: LABR‐312 (low-dose)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LABR‐312 (low-dose)
Trial: 23351827
Drug: LABR‐312 (high-dose)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LABR‐312 (high-dose)
Trial: 11703951
Drug: Eptifibatide 135
RxNorm normalized name: Eptifibatide
DrugBank: Eptifibatide (DB00063)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eptifibatide 135 microg/kg bolus followed by 0.75 microg/kg/min infusion
Trial: 11703951
Drug: Eptifibatide 180
RxNorm normalized name: Eptifibatide
DrugBank: Eptifibatide (DB00063)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eptifibatide 180 microg/kg bolus followed by 2.0 microg/kg/min infusion
Trial: 11703951
Drug: Eptifibatide 250
RxNorm normalized name: Eptifibatide
DrugBank: Eptifibatide (DB00063)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eptifibatide 250 microg/kg bolus followed by 3.0 microg/kg/min infusion
Trial: 9141536
Drug: [Nle27]GHRH-(1-29)-NH2 at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: [Nle27]GHRH-(1-29)-NH2 at a dose of 10 microg/kg, administered nightly for 16 weeks after 4 weeks of placebo.